# LifeMD, Inc.: Form 10-Q/A for the period ended Sep 30, 2016

- Company: [LifeMD, Inc.](/companies/lfmd.md) (CIK 948320)
- Form: 10-Q/A
- Filed: 2017-11-13
- Accepted by EDGAR: Nov 13, 2017, 15:55 ET
- Period: 2016-09-30
- Accession: 0001213900-17-011833
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/948320/000121390017011833/f10q0916a1_immudyneinc.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/948320/000121390017011833/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-07-01 to 2016-09-30 | $1.4m | us-gaap:Revenues |
| Revenue | 9 months, 2016-01-01 to 2016-09-30 | $4.3m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-07-01 to 2016-09-30 | $388.2k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2016-01-01 to 2016-09-30 | $1.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2016-07-01 to 2016-09-30 | $996.2k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2016-01-01 to 2016-09-30 | $3.0m | us-gaap:GrossProfit |
| Operating income | 3 months, 2016-07-01 to 2016-09-30 | −$207.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-01-01 to 2016-09-30 | −$466.4k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-07-01 to 2016-09-30 | $10.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2016-01-01 to 2016-09-30 | $15.8k | us-gaap:InterestExpense |
| Net income | 3 months, 2016-07-01 to 2016-09-30 | −$226.7k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-01-01 to 2016-09-30 | −$488.7k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-07-01 to 2016-09-30 | $34427087.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2016-01-01 to 2016-09-30 | $31917873.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-07-01 to 2016-09-30 | $34427087.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2016-01-01 to 2016-09-30 | $31917873.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 9 months, 2016-01-01 to 2016-09-30 | −$111.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2016-09-30 | $473.9k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-09-30 | $1.1m | us-gaap:AssetsCurrent |
| Total assets | at 2016-09-30 | $1.1m | us-gaap:Assets |
| Current liabilities | at 2016-09-30 | $622.3k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2016-09-30 | $300.0k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 31,581 characters.

### Overview

We manufacture, distribute and sell natural immune support products; namely proprietary yeast beta glucans which are natural extracts that have been shown through testing and analysis and scientific research to support the immune system. Yeast beta glucans are classified as generally recognized as safe (“GRAS”) by the Food and Drug Administration (“FDA”). We are and have been a science driven company for more than 25 years. Our products are used in oral and topical applications. Historically, we have sold our proprietary additives, for both oral and topical use, primarily via business-to-business to large dietary supplement and cosmetic companies. During fiscal year 2015 we have seen increased interest in our proprietary GRAS topical delivery system, which we believe may have additional beneficial and marketable uses (both topically and orally) and on which are conducting further testing. In addition, during the fourth quarter of 2015, we established a joint venture, that does business under the name Innate Scientific LLC (“Inate”), to launch a complete skin care regimen that contains our proprietary ingredients, and which contributed to our revenues in the first nine months of 2016. The Company entered into a limited liability company operating agreement with its joint venture partners with respect to Inate under the legal name Immudyne PR LLC (“Immudyne PR”). On April 1, 2016, the original operating agreement was amended and restated and we increased our ownership and voting interest in Immudyne PR to 78.16667%. As a result of our ownership and control of Immudyne PR, we now operate in two business segments, nutraceutical and cosmetic additives and finished cosmetic products.

We have performance based contracts with our sales and marketing executives, which allows us to continue to maintain a relatively low overhead. Our priority is to pursue opportunities to market our products and increase sales. We expect that a significant component of our selling, general and administration expenses going forward will consist of equipment leasing costs relating to improving our operating efficiencies, as well as conducting new studies which could open new markets. These aforementioned costs, along with the additional costs resulting from our operations as a public reporting company, could adversely impact our future results of operations. Additional significant factors that we believe will affect our operating results going forward are: (i) protection of our intellectual property rights; (ii) imposition of more stringent government regulations of our products; and (iii) marketing expenses.

We historically have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products. We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive position in the marketplace. For several years, we were involved in complex litigation regarding patents and licenses critical to our products. In 2010, we prevailed on all major legal matters and reached favorable settlements. If additional litigation becomes necessary to protect our intellectual property rights, such litigation may be costly, divert our management’s attention away from our core business and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would result in an outcome favorable to us. In addition, yeast beta glucans are designated as GRAS under current FDA regulations. Future government regulations may prevent or delay the introduction or require the reformulation of our products. Some agencies, such as the FDA, could require us to remove a particular product from the market, delay or prevent the import of raw materials for the manufacture of our products or otherwise disrupt the marketing of our products. Any such government actions could result in additional costs to us, reduced growth prospects, lost sales from products that we are required to remove from the market and potential product liability litigation.

We have historically operated with limited capital and have funded operations in the past through the sales of our products and loans and advances from Mark McLaughlin, our President, and other directors. In 2015 we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as of December 31, 2015. In addition, in November 2015, we established a $100,000 line of credit with a commercial lender for our short-term working capital needs, which has since been repaid in full. In the third quarter of 2016 the Company sold $150,000 of 11% subordinated promissory notes due in six (6) months in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company’s common stock. We plan on our operating business (in conjunction with our short term non-dilutive borrowings) to be able to fund operations through 2016. However, in the event we require additional operating capital we may have to depend on sources other than operating revenues to meet our operating and capital needs. No assurance can be given that such sources will be available, and no assurance can be given that Mr. McLaughlin or other directors who have in the past willingly funded operations will commit to do so in the future, or that we will be successful in our endeavors to raise additional capital. For additional information regarding these and other risks please see our Annual Report on Form 10K for the fiscal year ended December 31, 2015 filed with the SEC on March 30, 2016.

### Results of Operations

### Three Months Ended September 30, 2016, Compared to the Three Months Ended September 30, 2015

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

|  | 2016 $% of Sales |  | 2015 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Sales | 1,384,429 |  | 279,883 |  |
| Cost of sales | 388,202 | 28% | 73,988 | 26% |
| Gross profit | 996,227 | 72% | 205,895 | 74% |
| Operating expenses | (1,203,931) | (87)% | (187,954) | (67)% |
| (Loss) Income from operations | (207,704) | (15)% | 17,941 | 6% |
| Interest (expense) | (9,992) | (1)% | (14,422) | (5)% |
| Income tax benefit | - | 0% | 4,600 | 2% |
| Net income (loss) | (217,696) | (16)% | 8,119 | 3% |
| Net income (loss) attributable to noncontrolling interests | 8,955 | 1% | - | 0% |
| Net income (loss) attributable to Immudyne, Inc. | (226,651) | (16)% | 8,119 | 3% |

Overall sales for the three months ended September 30, 2016 were $1.38 million, an increase of 395% from $280,000 for the same period in 2015. Our increase in sales was primarily attributable to sales made by our finished cosmetic products segment of $1.15 million through our joint venture with Inate, which did not operate in the period ended September 30, 2015. Net sales for our nutraceutical and cosmetic additives segment remained relatively consistent between periods at $0.22 million and were in line with our expectations.

Cost of sales consists primarily of material costs, labor costs and related overhead directly attributable to the production of our products. Total cost of sales increased 425% to $388,000 in the third quarter of 2016 compared to $74,000 for the same period in 2015, which costs in the 2015 period were solely attributable to our nutraceutical and cosmetic additives product segment. The increase in our cost of sales was due to our finished cosmetic products segment, which costs were not incurred in the third quarter of 2015.

Gross profit increased 384% to $996,000 in the third quarter of 2016 compared to $206,000 for the same period in 2015 as a result of our overall increased sales due to sales made through our joint venture, which such sales we did not have in the prior period. Gross profit as a percentage of sales decreased to 72% in the third quarter of 2016 from 74% for the same period in 2015 due to the shift in the composition of our sales between periods from solely topical and oral additives to primarily finished products sold through Inate, which products generally have lower margins.

Operating expenses consisted of general and administrative expense, advertising and marketing expenses, compensation and related expense and professional fees. Overall operating expenses increased 538% to approximately $1.2 million in the third quarter of 2016 from approximately $188,000 for the same period in 2015, primarily due our increased advertising and marketing expenses incurred to generate our increase in sales and increased compensation related expenses with respect to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. The increase in our overall operating expenses was also due to our increase in sales. General and administration expense increased 253% to approximately $205,000 in the third quarter of 2016 from approximately $58,000 for the same period in 2015. Compensation and related expense increased 258% to approximately $362,000 in the third quarter of 2016 from approximately $101,000 for the same period in 2015 due to the aforementioned share issuance. Professional fees increased 186% to approximately $83,000 in the third quarter of 2016 from approximately $29,000 for the same period in 2015, due to increased legal and accounting fees incurred with respect to Inate’s operations. Marketing expenses increased to approximately $555,000 due to expenses incurred with respect to our direct to consumer business.

Net loss attributable to Immudyne in the third quarter of 2016 was approximately $218,000 compared to net income of $8,000 for the same period in 2015. We consolidated the operations of our joint venture, Inate, and reflected a non-controlling interest for 21.833% of these operations. Net loss attributable to Immudyne, Inc. as a percentage of sales was 16% in the third quarter of 2016 compared to net income as a percentage of sales of 3% for the same period in 2015. Our net loss notwithstanding our substantial increase in sales was primarily due to the advertising and marketing expenses we incurred in the quarter to help generate sales and our increased compensation expenses due to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. We believe these costs will decrease as a percentage of sales over the course of the fiscal year as Inate continues to mature as a business.

### Nine Months Ended September 30, 2016, Compared to the Nine Months Ended September 30, 2015

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales:

|  | 2016 $% of Sales |  | 2015 $% of Sales |  |
| --- | ---: | ---: | ---: | ---: |
| Sales | 4,252,704 |  | 845,513 |  |
| Cost of sales | 1,268,319 | 30% | 237,707 | 28% |
| Gross profit | 2,984,385 | 70% | 607,806 | 72% |
| Operating expenses | (3,450,816) | (81)% | (599,201) | (71)% |
| (Loss) Income from operations | (466,432) | (11)% | 8,605 | (1)% |
| Interest (expense) | (15,805) | 0% | (33,048) | (4)% |
| Income tax benefit | - | 0% | 13,200 | 2% |
| Net loss | (482,237) | (11)% | (11,243) | (1)% |
| Net income attributable to noncontrolling interest | 6,439 | 0% | - | 0% |
| Net loss attributable to Immudyne, Inc. | (488,676) | (11)% | (11,243) | (1)% |

Overall sales for the nine months ended September 30, 2016 were $4.25 million, an increase of 403% from $845,000 for the same period in 2015. Our increase in sales was primarily attributable to sales made by our finished cosmetic products segment of $3.49 million through our joint venture with Inate, which did not operate in the period ended September 30, 2015. Net sales for our nutraceutical and cosmetic additives segment remained relatively consistent between periods at $780,000 and were in line with our expectations.

Cost of sales consists primarily of material costs, labor costs and related overhead directly attributable to the production of our products. Total cost of sales increased 434% to $1.27 million for the nine months ended September 30, 2016 compared to $238,000 for the same period in 2015, which costs in the 2015 period were solely attributable to our nutraceutical and cosmetic additives product segment.

Gross profit increased 391% to $2.98 million in the nine months ended September 30, 2016 compared to $608,000 for the same period in 2015 as result of our increased sales. Gross profit as a percentage of sales decreased to 70% for the nine months ended September 30, 2016 from 72% for the same period in 2015 due to the shift in the composition of our sales between periods from solely topical and oral additives to primarily finished products through Inate, which products generally have lower margins.

Operating expenses consisted of general and administrative expense, compensation and related expense and professional fees. Overall operating expenses increased 476% to $3.45 million in the nine months ended September 30, 2016 from $599,000 for the same period in 2015. The increase in our overall operating expenses was due primarily to our operation of Inate in the 2016 year whereas we only had operations in our nutraceutical and cosmetic additives segment in the comparable 2015 period and due to our significant up-front advertising and marketing expenses ($1.71 million) incurred to generate our significant increase in sales from our finished cosmetic products segment, which costs were not incurred in the 2015 period. General and administration expense increased 85% to $383,000 for the nine months ended September 30, 2016 from $207,000 for the same period in 2015. Compensation and related expense increased 258% to $1.08 million in the nine months ended September 30, 2016 from $301,000 for the same period in 2015 due primarily to increased compensation related expenses with respect to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. Professional fees increased 205% to $277,000 for the nine months ended September 30, 2016 from approximately $91,000 for the same period in 2015, due to increased legal and accounting fees incurred with respect to Inate’s operations. Marketing expenses increased to $1.71 million due to expenses incurred with respect to our direct to consumer business.

Net loss attributable to Immudyne in the nine months ended September 30, 2016 was approximately $482,000 compared to net loss of $11,000 for the same period in 2015. We consolidated the operations of our joint venture, Inate, and reflected a non-controlling interest for 21.833% of these operations. Net loss attributable to Immudyne, Inc. as a percentage of sales was 11% in nine months ended September 30, 2016 compared to net loss as a percentage of sales of 1% for the same period in 2015. Our net loss notwithstanding our substantial increase in sales was primarily due to the substantial up-front advertising and marketing expenses we incurred to help generate sales through our recently formed joint venture, Inate, and our increased compensation expenses due to shares issued to the Company’s joint venture partners pursuant to previously disclosed service agreements. We believe these costs will decrease as a percentage of sales as Inate continues to mature as a business.

### Liquidity and Capital Resources

Our principal demands for liquidity are to increase sales, purchase inventory and for sales distribution and general corporate purposes. We incurred negative operating cash flows in the 2015 and 2014 fiscal years and for the first three quarters of 2016. As a result, our auditors have raised substantial doubt about our ability to continue as a going concern. We plan on our operating business (in conjunction with our short term non-dilutive borrowings) being able to fund operations through 2016. However, if necessary, we may raise additional capital through a private placement of common stock, obtaining debt financing or from advances from our President and/or directors; however, no assurances can be made that we will be successful in our endeavors to raise additional capital.

In 2015 we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as of December 31, 2015. In addition, in November 2015, we secured a $100,000 line of credit with a commercial lender for our short-term working capital needs, which has since been repaid in full. In the third quarter of 2016 the Company sold $150,000 of 11% subordinated promissory notes due in six (6) months in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company’s common stock.

There can be no assurance that required future financing can be successfully completed on a timely basis, or on terms acceptable to us. Any future issuance of equity securities could cause dilution to our shareholders. Any incurrence of indebtedness would increase our debt service obligations and would cause us to be subject to restrictive operating and financial covenants.

We had net working capital of approximately $457,066 at September 30, 2016, resulting in an increase from net working capital of approximately ($136,841) at September 30, 2015. The ratio of current assets to current liabilities was 1.7 to 1 at September 30, 2016.

The following is a summary of cash provided by or used in each of the indicated types of activities during the nine months ended September 30, 2016 and 2015:

| Cash provided by (used in): | 2016 | 2015 |
| --- | ---: | ---: |
| Operating activities | $(111,698) | $(80,311) |
| Financing activities | 352,635 | 78,678 |

Net cash flow used by operating activities was $0.11 million for the nine months ended September 30, 2016, compared to net cash flow used in operating activities of $0.08 million for the same period in 2015. The increase in the amount of cash used by our operating activities was due to up-front advertising and marketing expenses incurred in the 2016 period. We expect that these expenses will decrease as a percentage of sales over the course of the fiscal year as Inate continues to mature as a business.

Net cash flows provided by financing activities was $0.35 million for the nine months ended September 30, 2016, compared to net cash flows provided by financing activities of $0.08 million for the same period in 2015 due to additional indebtedness incurred during the period as further described below.

### Indebtedness

From time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs. In 2015 we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as of December 31, 2015. In addition, in November 2015, we secured a $100,000 line of credit with a commercial lender for our short-term working capital needs, which has since been repaid in full. In the third quarter of 2016 the Company sold $150,000 of 11% subordinated promissory notes due in six (6) months in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company’s Common Stock.

We are subject to a royalty agreement pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain skin care products up to $227,175. During the year ended December 31, 2015 our sales reached the maximum amount under which we are required to pay a royalty under this agreement. Royalty expense amounted to $0 and $20,157 for the nine months ended September 30, 2016 and 2015, respectively. During 2015, our President, who has a 60% interest in the royalties, converted all royalties payable (in the amount of $84,868) to 499,225 shares of the company’s stock valued at $0.17 cents a share.

### Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to shareholders.

We have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

### Critical Accounting Policies

While our significant accounting policies are described more fully in Note 2 to our financial statements, we believe the following accounting policies are the most critical to aid you in fully understanding and evaluating this management discussion and analysis.

#### Basis of Presentation and Use of Estimates

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the U.S., or U.S. GAAP. In preparing financial statements in conformity with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Significant estimates required by management include the valuation of inventory and stockholders’ equity-based transactions. Actual results could differ from those estimates.

#### Inventory

Inventory is valued at the lower of cost or market value with cost determined on a first-in, first-out basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down their inventories to market value, if lower.

#### Revenue Recognition

The Company’s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer’s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $530,000 and $1,578,000 in the three-month and nine-month periods ended September 30, 2016, respectively. Customer discounts, returns and rebates were not significant in the three-month and nine-month periods ended September 30, 2015.

Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer’s delivery site, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company’s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.

#### Stock-based Compensation

The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of our shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, estimated forfeiture rate included in the option valuation was zero. Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.

#### Noncontrolling Interests

The Company accounts for its less than 100% interest in Inate in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of Inate net loss attributable to noncontrolling interests in the consolidated statement of operations.

### New Accounting Pronouncements

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting,” which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements.

In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements.

In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.

In July 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The Company is in the process of evaluating the impact of this ASU on its consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.

All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.

## Controls and procedures

As filed, 2,736 characters.

### Disclosure Controls and Procedures

We carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer (“PEO”), who is also our Principal Financial Officer (“PFO”), of the design and effectiveness of our “disclosure controls and procedures” (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective. The conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment as the Company had only one officer; (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; and (iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no written whistleblower policy. If and when sufficient funds are available, our PEO/PFO plans to implement appropriate disclosure controls and procedures to remediate these material weaknesses, including (i) appointing additional qualified personnel to address inadequate segregation of duties and ineffective risk management; (ii) adopt sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy; and (iii) implement sufficient security and restricted access measures regarding our computer systems and implement a disaster recovery plan.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2016, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

## Risk factors

As filed, 145 characters.

You should consider carefully the factors discussed in the “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015.

Filed Nov 13, 2017.
Source: SEC EDGAR, the filing index for accession 0001213900-17-011833. Last ingested by Listed: Nov 13, 2026, 16:33 ET. No prices; not investment advice.
